Coherus Declares CVR Dividend, Launches Sale of Legacy Biosimilars
CHRS sits 21% above its 52-week low of $1.02.
Summary
Coherus Oncology is issuing a special dividend of contingent value rights tied to future monetization of its legacy biosimilar assets, and has begun a sale process for those assets. This follows the company's Q2 report showing $105.3M in cash and a narrower loss, and a recent $55M debt refinancing. The CVR structure lets shareholders capture upside from asset sales without immediate cash outlay, while the sale process could bring in non-dilutive capital. The move signals a strategic pivot toward LOQTORZI and pipeline development. Watch for announcements of interested buyers or deal terms for the biosimilar portfolio.
At the time of this announcement, CHRS was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $177.7M. The 52-week trading range was $1.02 to $2.62. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.